Last reviewed · How we verify
NCT04883671
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial
NA trial testing Standard of Care in Adenoid Cystic Carcinoma in 32 participants. Currently enrolling.
1 June 2028
Quick facts
| Lead sponsor | Dana-Farber Cancer Institute |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 27 December 2021 |
| Primary completion | 1 June 2028 |
| Estimated completion | 1 June 2030 |
| Sites | 5 locations across United States |
Drugs / interventions tested
- Standard of Care
- SBRT — full drug profile →
Conditions studied
- Adenoid Cystic Carcinoma — all drugs for Adenoid Cystic Carcinoma →
- Metastatic Adenoid Cystic Carcinoma — all drugs for Metastatic Adenoid Cystic Carcinoma →
Sponsor
Dana-Farber Cancer Institute
Who can join
18 and older, any sex, with Adenoid Cystic Carcinoma or Metastatic Adenoid Cystic Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival. The name(s) of the study intervention involved in this study is: * Stereotactic Body Radiation Therapy (SBRT)
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Approaches to the Management of Metastatic Adenoid Cystic Carcinoma.
Lee RH, Wai KC, Chan JW, Ha PK, et al · · 2022 · cited 35× · PMID 36428790 · DOI 10.3390/cancers14225698 -
Survival outcomes of pulmonary metastasis-directed local therapy in adenoid cystic carcinoma.
Hoff CO, Feng L, Bonini F, Sousa LG, et al · · 2025 · cited 2× · PMID 40377125 · DOI 10.1002/cncr.35901 -
Real-world treatment patterns and survival outcomes in metastatic head and neck adenoid cystic carcinoma.
Bölek H, Kayaalp M, Şahin TK, Doğan OT, et al · · 2025 · PMID 41029524 · DOI 10.1186/s12885-025-14884-5
Verify or expand the search:
- PubMed search for NCT04883671
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Standard of Care
Trials testing the same drug.
- NCT07337655 — Efficacy and Safety of Aspirin and Lansoprazole for Prevention of Preterm Birth in High-Risk Pregnant Women: A Biomarker · Phase 2, PHASE3 · not yet recruiting
- NCT07018466 — Tele-Exercise for MERP · NA · not yet recruiting
- NCT06930768 — Evaluating the Efficacy of NeoThelium FT in the Treatment of Venous Leg Ulcers · NA · not yet recruiting
- NCT06918548 — Evaluating the Efficacy of NeoThelium FT in the Treatment of Pressure Injuries · NA · not yet recruiting
- NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
Other recruiting trials for Adenoid Cystic Carcinoma
Currently open trials in the same condition.
- NCT07320508 — Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study · Phase 2 · recruiting
- NCT06805617 — A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers · Phase 2 · recruiting
- NCT06805825 — A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres · Phase 1 · recruiting
- NCT06781567 — Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma · Phase 2 · recruiting
- NCT06118086 — Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma · Phase 1, PHASE2 · recruiting
Other Dana-Farber Cancer Institute trials
Trials by the same sponsor.
- NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
- NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
- NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
- NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
- NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04883671 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
- Last refreshed: 23 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04883671.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing